Investigational drugs in recent clinical trials for treatment-resistant depression

Ricardo P. Garay, Carlos A. Zarate Jr, Thomas Charpeaud, Leslie Citrome, Christoph U. Correll, Ahcène Hameg & Pierre-Michel Llorca

To cite this article: Ricardo P. Garay, Carlos A. Zarate Jr, Thomas Charpeaud, Leslie Citrome, Christoph U. Correll, Ahcène Hameg & Pierre-Michel Llorca (2017): Investigational drugs in recent clinical trials for treatment-resistant depression, Expert Review of Neurotherapeutics, DOI: 10.1080/14737175.2017.1283217

To link to this article: http://dx.doi.org/10.1080/14737175.2017.1283217

Accepted author version posted online: 16 Jan 2017.
Investigational drugs in recent clinical trials for treatment-resistant depression

Ricardo P. Garay\textsuperscript{a,*}, Carlos A. Zarate Jr\textsuperscript{b}, Thomas Charpeaud\textsuperscript{c}, Leslie Citrome\textsuperscript{d}, Christoph U. Correll\textsuperscript{e,f}, Ahcène Hameg\textsuperscript{a} & Pierre-Michel Llorca\textsuperscript{c}

\textsuperscript{a}Pharmacology and Therapeutics, Craven, Villemoisson-sur-Orge, France

\textsuperscript{b}Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.

\textsuperscript{c}Centre Médico-Psychologique B, CHU, Clermont-Ferrand, EA U7280, Université d’Auvergne, France

\textsuperscript{d}Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY, USA.

\textsuperscript{e}The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, New York, USA

\textsuperscript{f}Hofstra Northwell Health School of Medicine, Hempstead, New York, USA

*Corresponding author: Ricardo P. Garay

Address: 46bis rue Gallieni, 91360 Villemoisson-sur-Orge, France; Tel: +33169048034/+33666468487; Fax: +33170248754; E-mail: ricardo.garay@orange.fr
Abstract

Introduction: The authors describe the medications for treatment-resistant depression (TRD) in phase II/III of clinical development in the EU and US and provide an opinion on how current treatment can be improved in the near future.

Areas covered: Sixty-two trials were identified in US and EU clinical trial registries that included six investigational compounds in recent phase III development and 12 others in recent phase II clinical trials. Glutamatergic agents have been the focus of many studies. A single intravenous dose of the glutamatergic modulator ketamine produces a robust and rapid antidepressant effect in persons with TRD; this effect continues to remain significant for 1 week. This observation was a turning point that opened the way for other, more selective glutamatergic modulators (intranasal esketamine, AVP-786, AVP-923, AV-101, and rapastinel). Of the remaining compounds, monoclonal antibodies open highly innovative therapeutic options, based on new pathophysiological approaches to depression.

Expert commentary: Promising new agents are emerging for TRD treatment. Glutamatergic modulators likely represent a very promising alternative to monoaminergic antidepressant monotherapy. We could see the arrival of the first robust and rapid acting antidepressant drug in the near future, which would strongly facilitate the ultimate goal of recovery in persons with TRD.

Keywords: AV-101, AVP-786, brexpiprazole, buprenorphine, cariprazine, clinical trials, esketamine, ketamine, rapastinel, treatment-resistant depression.
1. Introduction

Although exact definitions and stringency levels vary, treatment-resistant depression (TRD) is commonly defined as a clinical entity grouping cases of major depressive disorder (MDD) that do not respond adequately to two successive trials of antidepressant treatment at an adequate dose and duration [1-3]. TRD is associated with severe impairment in cognitive functioning, increased risk of developing/ being associated with comorbid illnesses, decreased workplace performance, increased risk of suicide and increased cost of care [4]. TRD is becoming a major threat to public health because TRD prevalence represents at least 15% to 30% of MDD cases [1, 2, 5-7], and MDD itself is one of the most commonly encountered mental disorders with a world-wide point prevalence rate of 4.7% [8].

It is commonly presumed that the variability in antidepressant treatment response reflects biological heterogeneity [9]. TRD is a complex, multifactorial and heterogeneous group of disorders, integrating neurobiological and environmental factors, which reduces the sensitivity to selective serotonin reuptake inhibitors (SSRIs) and second-line antidepressants [10-12]. Among these factors, converging lines of evidence indicate an important pathophysiological role of the glutamatergic system [13, 14]. Recent evidence is suggesting that TRD may involve a maladaptive response to stress in early life, leading to disturbances characterized by a complex cross-talk within the extra-synaptic glutamatergic receptor signal pathway, involving glutamate reuptake and release by glial cells [14].

Extensive evidence supports the use of atypical antipsychotics as possible adjunctive therapy for the management of TRD [1, 7]. Four atypical antipsychotics have been approved by the FDA (Food and Drug Administration) as treatments for MDD: aripiprazole, quetiapine extended-release, and brexpiprazole, in combination with antidepressants, and olanzapine combined with fluoxetine specifically [1, 15-17]. Of these four choices, only olanzapine-
fluoxetine combination has the indication for TRD, while the others are indicated for MDD insufficiently responding to first-line antidepressant treatment [15]. Use of adjunctive atypical antipsychotics for MDD can be associated with significant side effects such as weight gain, akathisia, and sedation [18]. Other combination therapies for TRD include lithium [19], thyroid hormone [20], buspirone [21], mirtazapine [22] and bupropion [23]. Of note, the STAR*D study found no clear-cut "winner" for improving clinical outcomes in real-world patients with TRD [24]. Moreover, the NICE Appraisal Committee recommended the new multimodal antidepressant, vortioxetine, as an option for treating TRD [25].

Cognitive behavioral therapy and other psychotherapies remain a treatment option, alone or in combination with pharmacotherapy [1, 26]. Neurostimulation and neuromodulation strategies (electroconvulsive therapy, repetitive trans-cranial magnetic stimulation, vagus nerve stimulation) are also available for subjects insufficiently responding to pharmacotherapy or psychosocial interventions [1, 27-30].

We aimed to evaluate how the pharmacotherapy of TRD may evolve in the near future by using a previously developed search strategy [31-33]. For this purpose, we used the US and EU clinical trial registries to obtain information about recent, still unpublished clinical trials on TRD. Among others, these registers inform about the characteristics and status of exploratory phase II studies (recruiting, ongoing, completed and results), the names of drugs entering pivotal phase III studies, and the rational and expected results of the trials, as expressed by the investigators themselves. This information was supplemented with data officially reported, either in publications or in meetings. Regular follow up reviews of this kind could provide a fresh look of current progress in the field, identify emerging problems, and anticipate the arrival of potentially effective drugs.
2. Methods

As done for other conditions before [31, 32], the medications in phase II and III trials of clinical development for the treatment of TRD, have been appraised using the clinical trial registries of the (National Institutes of Health (NIH), USA and the European Medicines Agency (EMA) and conducting systematic reviews of electronic data bases on identified compounds.

2.1 Identification of recent phase II/III clinical trials in TRD

Clinical trial registries operated and maintained by the US NIH (ClinicalTrials.gov, www.clinicaltrials.gov) and the EMA (EU Clinical Trials Register, www.clinicaltrialsregister.eu) were accessed to identify recent phase II and phase III clinical pharmacological trials in TRD. Clinical trials investigating psychosocial interventions or neurostimulation strategies were not assessed, but the interested reader is referred elsewhere [1, 26-29]. Regulatory guidelines, such as the EMA’s draft guideline for the clinical investigation of medicines in depression (including TRD) are also available elsewhere [34]. Identified clinical trials were given with their designated name, a literature reference, or the database identifier number, in decreasing order of priority.

2.1.1 Selection criteria

In order to be retained for this review, pharmacologic agents needed to be in phase II and/or III clinical trials for TRD and have at least one trial satisfying the following criteria:

1. Trial updated on January 1st, 2014 or later,
2. Trial not terminated (does not apply for new compounds),
3. Trial status known,
4. Completion date by January 1st, 2013 or later.
In case that data were not posted in clinical trial registries or in case of unpublished data, we requested information from the principal or lead investigator of the study in question.

2.1.2 Search of clinical trials

Clinical trials with the above characteristics were searched in the ClinicalTrials.gov database, using the following search terms: “treatment-resistant depression”, “treatment-refractory depression” or “difficult-to-treat depression” (for “conditions”); “drug” (for “interventions”); “Phase 2” or “Phase 3” (for “phase”). Similar search terms were used for the EMA database. Trials in MDD (for “conditions”) that were conducted in TRD patients were also retained for the analysis.

2.2 Additional sources of information

We searched electronically for articles related to the compounds identified in the clinical trial registries, particularly those published from 2012 to the present, using the name of the compound AND “treatment-resistant depression”, OR “depression”. The following biomedical literature search resources were used: PubMed (www.ncbi.nlm.nih.gov/pubmed), Science Direct (www.sciencedirect.com), Google Scholar (https://scholar.google.com), and Cochrane Library (www.cochranelibrary.com).

The above information was supplemented by publically available information from the EMA (www.ema.europa.eu) and FDA (www.fda.gov), presentations at international congresses, references cited in articles and books, and clinical practice recommendations (CPR). We also consulted the websites of pharmaceutical and biotech companies active in the field of psychiatry.

2.3 Extraction of investigational compounds and relevant trial data
We extracted the names of compounds and trials sponsors, together with their associated data regarding efficacy and tolerability/side-effects, the duration of the study, number of patients and results (if available). Unless otherwise indicated, compounds were administered orally.

3. Compounds undergoing phase III clinical development for TRD

The clinical trial registries of the NIH (www.clinicaltrials.gov) and the EMA (www.clinicaltrialsregister.eu) were accessed from March 18th, 2016 to December 21st, 2016. These databases included eighteen phase III clinical trials on TRD updated on January 1st, 2014 or later. Three clinical trials were excluded from the present analysis for the following reasons: primary completion date before 2013 (bupropion), terminated trials (olanzapine–fluoxetine combination) and no investigational drug (pulsating electromagnetic fields). The remaining fifteen phase III clinical trials that fulfilled the inclusion criteria, concerned the following six investigational compounds. (Table 1 and Figure 1): ketamine [35-60], esketamine [43, 60-65], buprenorphine [66-70], ALKS 5461 [71, 72], brexpiprazole [17, 73, 74] and cariprazine [75-77] (trials with ALKS 5461, brexpiprazole and cariprazine have indicated “MDD” for “conditions”, but were conducted in patients who meet some definitions of TRD).

3.1 Ketamine

3.1.1 Background

Ketamine acts primarily as a glutamatergic modulator, but also as a partial agonist at dopamine D2 receptors and as a dopamine reuptake inhibitor [43, 44, 47, 57]. As glutamatergic agent, ketamine is a N-methyl-D-aspartate receptor (NMDAR) antagonist [43, 44]. A recent study in mice showed that a ketamine metabolite is essential for its antidepressant effects [57, 59]. The antidepressant action of this metabolite is independent of
NMDAR inhibition, but involves early and sustained activation of α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors (AMPARs) [57].

Ketamine is a general anesthetic, which has been used for over forty years because of its short half-life (180 minutes), the lack of respiratory depression and its good safety profile [40]. Unfortunately, a significant first-pass hepatic metabolism limits the available routes of administration for non-anesthetic uses.

Early clinical studies suggested that sub-anesthetic doses of intravenous ketamine were effective and rapid acting in major depression [35-37]. In 2006, a randomized controlled trial (RCT) by Zarate et al. [39] demonstrated that a single intravenous dose of ketamine produced a robust and rapid antidepressant effect in persons with TRD, which continued to remain significant for one week. Ketamine efficacy was confirmed and extended in several randomized trials involving more than 200 persons with depression [41, 42, 46]. The limited duration of the antidepressant effect after a single dose (not exceeding 72 hours to one week) was confirmed by most studies [41, 42, 46].

Ketamine is a generic medication, and it was being studied at academic medical centers in eight out of nine recent clinical trials (Table 2).

3.1.2 Phase II clinical trials

The clinical trial registries of the NIH and the EMA included seven recent phase II clinical trials of ketamine in TRD (Table 2). NCT01627782 showed that administering intravenous ketamine two or three times weekly (0.5 mg/kg) similarly maintained antidepressant efficacy over 15 days [38]. NCT01920555 is a dose finding, multisite NIMH sponsored study (there is still concern about the optimal dose for efficacy and safety). Three other RCTs (NCT02360280, NCT01868802 and EudraCT 2010-023414-31) are currently recruiting
participants to investigate the efficacy, safety, tolerability, dosage and/or durability of sub-anesthetic intravenous ketamine in TRD (see Table 2 for details).

Two open-label phase II trials will further study ketamine in TRD. NCT02078817 will investigate intravenous sub-anesthetic ketamine for adolescents with TRD. NCT02094898 will investigate if low-dose ketamine infusions reduce depression severity and suicide risk.

3.1.3 Phase III clinical trials

Two phase III clinical trials have been designed to investigate ketamine in TRD. NCT02556606 will compare the effectiveness of a single infusion of ketamine or midazolam (a short-acting benzodiazepine) in persons with late-life TRD (non-responders to two or more adequate trials of FDA-approved antidepressants, as determined by the Antidepressant Treatment Response Questionnaire (ATRQ) criteria. As of this writing, this study was not yet open for patient recruitment. NCT01945047 (phase II/III study) is recruiting participants to investigate the beneficial effects of a single ketamine injection as a rapid intervention for TRD (failure to respond adequately to at least two antidepressants and two augmentation strategies), and to investigate the possibility of obtaining a prolonged antidepressant effect with repeated injections (N≤3). Midazolam will be used for comparison.

3.2 Intranasal esketamine

3.2.1 Background

Esketamine (Janssen R&D, USA) is the S-enantiomer of ketamine, which possesses a threefold to fourfold higher affinity for NMDA receptors and greater anaesthetic potency than the R-ketamine enantiomer (arketamine) [43, 60, 64, 65]. The availability of an intranasal formulation led Janssen R&D to launch a development program, including three phase II and five phase III clinical trials (Table 3).

3.2.2 Phase II clinical trials
A phase II RCT (NCT01640080, Table 3 and ref. [64]) assessed the efficacy of intravenous esketamine in improving symptoms of depression in patients with TRD. A rapid (within 2 hours) and robust antidepressant effect was observed after a 40-min infusion of either 0.20 mg/kg or 0.40 mg/kg of esketamine as compared with placebo (Table 3 and ref. [64]). Another phase II RCT (SYNAPSE, NCT01998958, Table 3 and ref. [61]) evaluated the efficacy and dose response of intranasal esketamine in improving depressive symptoms in persons with TRD. Results from one of two panels of the multicenter study were reported at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting (Miami, USA, June 22-25, 2015) [61]. Over a one-week period, changes in MADRS total scores on Day 8 in all three esketamine treatment groups (28-mg, 56-mg and 84-mg) were statistically superior to placebo. Transient elevations in blood pressure (maximum mean changes= 19 mmHg for systolic and 10 mmHg for diastolic blood pressure, respectively) and heart rates were observed in a majority of patients receiving esketamine on dosing days. Dissociative symptoms abated with repeated dosing [61]. Preliminary data from a third phase II RCT (PeRSEVERe) showed that intranasal esketamine reduced depression symptoms at day 1 (4 hours post-dose; primary outcome criterion) and thoughts of suicide in high-risk depressed patients (Table 3 and ref. [63]).

Following the above positive results, the FDA granted a Breakthrough Therapy Designation (BTD) for intranasal esketamine in MDD with imminent risk for suicide [78] (breakthrough therapy is an FDA designation that expedites drug development), and esketamine entered phase III development as add-on therapy to oral antidepressants in TRD.

3.2.3 Phase III clinical trials

TRANSFORM-1 (NCT02417064) and TRANSFORM-2 (NCT02418585) are recruiting participants to evaluate the efficacy, safety and tolerability of fixed and flexible doses of
intranasal esketamine respectively in TRD (defined by nonresponse to 2 or more oral antidepressant treatments taken at adequate dosage and for adequate duration, assessed using the Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (MGH-ATRQ) (Table 3). TRANSFORM-3 (NCT02422186) will evaluate intranasal esketamine in the elderly (Table 3). SUSTAIN-1 (NCT02493868) will evaluate intranasal esketamine for relapse prevention and SUSTAIN-2 (NCT02497287) is a long-term safety and efficacy study (Table 3).

3.3 Buprenorphine

3.3.1 Background

Buprenorphine, a semisynthetic opioid derivative of thebaine, is a partial agonist at μ-opiate receptors, an antagonist of κ-receptors, and also displays affinity for δ-receptors (Table 1 and reference [66]). Buprenorphine is used as an analgesic at lower dosages (0.2 to 1.2 mg/d, sublingual or parenteral) to control moderate to severe pain and at higher dosages (0.8 to 4 mg/d) to treat opioid addiction [66].

Opiates were used to treat major depression until the mid-1950s [69]. In the 1990s, the advent of buprenorphine and other opioids with reduced dependence and abuse liabilities has made their re-evaluation possible for this indication. Two open-label pilot studies suggested a possible role for buprenorphine in treating depressive symptoms in people with opioid addiction [79] and in patients with TRD [69]. In addition, successful treatment of severe non-suicidal self-injury with buprenorphine has been reported in six individuals [70].

3.3.2 Recent phase II clinical trials

Buprenorphine is a generic medication, which is being studied at academic medical centers (Table 4). Recently, Karp et al. [67] conducted a pilot, one arm phase II trial (BUILD, NCT01071538) designed to investigate the safety and clinical effect of low-dose sublingual
buprenorphine (mean dose = 0.4 mg/d) in older adults with TRD. The mean (±SD) MADRS score decreased from 27.0 ± 7.3 at baseline to 9.5 ± 9.5 at week 8, with a sharp decline in depression severity during the first three weeks of exposure (mean change = -15.0 ± 7.9). Buprenorphine was well tolerated (there were no sustained elevations of systolic or diastolic blood pressure) [67].

Two phase I/II RCT (IRLGREY-B and IRL Grey B, or NCT02263248 and NCT02181231) have been designed to investigate the feasibility, safety, and tolerability of adjunctive buprenorphine (0.2 to 2 mg/d) in patients (≥50 years) in whom venlafaxine XR did not relieve the depressive symptoms (“difficult to treat depression”, Table 4). NCT02263248 is currently recruiting participants, and NCT02181231 is not yet open for participant recruitment.

3.3.3 Phase III clinical trials

BUP-TRD (NCT01407575) was a phase III RCT comparing the safety and efficacy of buprenorphine with placebo for adults with TRD (Table 4). The trial was completed in January 2014, with only 13 included patients. Blood pressure and heart rate were higher in patients treated on buprenorphine compared with those on placebo.

3.4 ALKS 5461

3.4.1 Background

ALKS 5461 (Alkermes, USA and Ireland) is a combination drug formulation of buprenorphine and the μ-opioid antagonist samidorphan [71, 72]. Samidorphan was added to counteract the μ-opioid agonist activity of buprenorphine and reduce its addictive potential [71]. Following positive phase II studies [72], ALKS-5461 entered phase III development (Table 4).

3.4.2 Phase III clinical trials
ALKS 5461 failed to meet pre-specified primary efficacy endpoint (change from baseline on the MADRS) in two of three core phase III trials (FORWARD-3, NCT02158546 and FORWARD-4, NCT02158533) [80] (Table 4). The third core phase III trial (FORWARD-5, NCT02218008) is currently ongoing, with completion date expected in October 2016. Two other phase III clinical trials (FORWARD-1, NCT02085135 and NCT02141399) are investigating safety and tolerability of ALKS 5461.

3.5 Brexpiprazole

3.5.1 Background

Brexiprazole (Rexulti®, Otsuka, Japan) is an atypical antipsychotic, acting as a partial agonist at dopamine D₂ receptors and as an antagonist at 5-HT₂A receptors [73, 74]. On July 2015, the FDA approved brexpiprazole as an add-on treatment to antidepressant medications for adults with MDD [73], based on a clinical development program that included two acute phase pivotal Phase III placebo-controlled trials [81, 82].

3.5.2 Phase III/IV clinical trials in TRD

NCT01838681 is a phase III/IV trial designed to investigate the maintenance of efficacy and safety during long-term treatment with adjunctive brexpiprazole in a large number of adult subjects with MDD and an inadequate response to antidepressant treatment (insufficient response to at least one and no more than three adequate antidepressant treatments) (Table 4). The study was recently completed, but results were not posted to ClinicalTrials.gov.

3.5.3 Other development studies

Additional phase III studies with brexpiprazole for agitation in dementia of the Alzheimer type are underway (NCT01862640 and NCT01922258) [32].

3.6 Cariprazine

3.6.1 Background
Cariprazine is a dopamine D₂ and D₃ partial agonist, with preferential affinity for dopamine D₃ receptors [31, 75, 76]. Animal studies revealed anti-anhedonic-like effects with cariprazine, suggesting potential utility to treat MDD [75].

3.6.2 Phase II clinical trials in TRD

One phase II RCT [76] evaluated the efficacy and safety of cariprazine as adjunctive therapy in patients with MDD who have inadequate response to standard antidepressant therapy (NCT01469377). Compared with placebo, reduction in MADRS total score at week 8 was significantly greater with adjunctive cariprazine 2-4.5 mg/d [76]. Cariprazine was generally well tolerated [76].

3.6.3 Phase III clinical trials in TRD

One phase III RCT evaluated the efficacy and safety of flexible doses of cariprazine as adjunctive therapy in patients with TRD (NCT01715805). Allergan and Gedeon Richter recently communicated that cariprazine did not have significant efficacy compared with placebo [77].

3.6.4 Regulatory aspects

In 2015, the FDA approved cariprazine to treat schizophrenia and manic or mixed episodes associated with bipolar I disorder [83].

4. Compounds in recent phase II clinical trials

The clinical trial registry of the NIH (www.clinicaltrials.gov; accessed from March 22nd, 2016 to June 15th, 2016) included 41 recent phase II clinical trials on TRD (trials last updated in January 1st, 2014 or later). Three additional phase II trials were found in the clinical trial registry of the EMA (www.clinicaltrialsregister.eu; accessed from March 23rd, 2016 to June 15th, 2016). Seventeen clinical trials were excluded from the present analysis for the following reasons: primary completion date before 2014 (SAMe), terminated trials (CERC-501, EVT
101), unknown recruitment status (riluzole), discontinued development (BMS 820836), compound in phase III clinical development (ketamine, esketamine, buprenorphine), no investigational drug (trans-cranial magnetic stimulation, pulsating electromagnetic fields, psychotherapy), other condition (obsessive-compulsive disorder, paediatric bipolar disorder, postsurgical abdominal pain, chronic hepatitis C, alcoholism).

A total of twenty-six phase II clinical trials fulfilled the inclusion criteria and were included in the analysis. Fourteen of these trials concerned compounds in phase III development, and were described in Section 3. The remaining thirteen trials concerned seven glutamatergic agents (AVP-923 [84-86], AVP-786 [87], CERC-301 [48, 88-90], AV-101 [91, 92], AZD6765 [93-95], rapastinel [96, 97] and RO4995819 [98-100]), two other psychotropic drugs (ziprasidone [101-104] and psilocybin [105, 106]) and three somatic drugs (minocycline [107-110], tocilizumab [111] and sirukumab [112]) (Table 1 and Figure 1). Some new glutamatergic agents were included in the analysis although they did not fully satisfy the inclusion criteria, i.e.: “condition” was MDD and not TRD (rapastinel, AV-101 and CERC-301) and RO4995819 development was terminated.

### 4.1 Glutamatergic agents

#### 4.1.1 AVP-923

4.1.1.1 Background

AVP-923 (Nuedexta®, Avanir, USA) is the first treatment for pseudo-bulbar affect (PBA) which was approved by the FDA [84] and the EMA [85]. PBA is characterized by uncontrollable episodes of crying and/or laughing/crying that occur in patients with types of CNS lesions (e.g., multiple sclerosis, amyotrophic lateral sclerosis).

AVP-923 is a fixed combination of dextromethorphan and quinidine [84, 85]. Dextromethorphan is a non-competitive NMDA receptor antagonist and σ₁-receptor agonist,
commonly used antitussive compound [113, 114] (for \( \sigma_1 \)-receptors in depression, see references [115, 116]). Quinidine is a CYP2D6 enzyme inhibitor, which serves to increase plasma concentrations of dextromethorphan and prolong its plasma half-life [84, 85].

4.1.1.2 Recent phase II clinical trials

NCT01882829 was a small one-arm phase II study designed to evaluate the efficacy, safety, and tolerability of AVP-923 in patients with TRD (Table 5). The primary outcome measure was the change in MADRS total score from baseline to week 10. The study was recently completed, but results are not yet posted on ClinicalTrials.com.

4.1.1.3 Other development studies

A recent phase II RCT (NCT01584440) showed that AVP-923 had statistical and clinical relevant efficacy for treating agitation in patients with Alzheimer disease (AD) and was generally well tolerated [32, 86].

4.1.2 AVP-786 (deuterated-dextromethorphan/quinidine combination)

4.1.2.1 Background

AVP-786 (Avanir, USA) is a new investigational compound consisting of a combination of deuterated (d6)-dextromethorphan and an ultra-low dose of quinidine [87]. The incorporation of deuterium serves to reduce dextromethorphan first-pass liver metabolism and quinidine dosage, potentially reducing the risk of drug interactions and cardiac effects [87].

4.1.2.2 Recent phase II clinical trials

NCT02153502 is a 10-week phase II RCT designed to evaluate the efficacy, safety, and tolerability of AVP 786 as an adjunctive therapy in patients with MDD and inadequate response to antidepressant treatment (less than 50% symptom reduction to at least 1 but no more than 3 adequate antidepressant trials during the current depressive episode) (Table 5). This study is currently recruiting participants.
4.1.2.3 Other development studies

Avanir Pharmaceuticals recently launched a phase III development program of AVP-786 for the treatment of agitation in patients with AD [32, 87].

4.1.3 CERC-301

4.1.3.1 Background

CERC-301 (MK-0657, Cerecor, USA) is a highly selective, orally bioavailable, NMDA receptor antagonist acting at the NMDA receptor 2B (NR2B) subunit [88-90]. CERC-301 showed acute antidepressant-like effects in the forced swim test (FST), a rat model of antidepressant efficacy [88]. A small RCT (N=5) conducted by Ibrahim et al. [89] suggested antidepressant efficacy for CERC-301 in TRD.

4.1.3.2 Recent phase II clinical trials

Paterson et al. [90] conducted a phase II RCT of adjunctive CERC-301 in subjects with severe depression and recent active suicidal ideation despite antidepressant treatment (NCT01941043, Table 5). CERC-301 was administered daily at a dose of 8 mg for 28 days and did not meet its primary endpoint (change in HDRS-17 at Day 7) [90].

NCT02459236 is another phase II RCT designed to evaluate the antidepressant effect of intermittent doses CERC-301 in TRD (Table 5). This study is currently recruiting participants.

4.1.3.3 Regulatory aspects

In November 2013, CERC-301 received Fast Track Designation by the FDA for the treatment of MDD [117].

4.1.4 AV-101

4.1.4.1 Background
AV-101 (4-chlorokynurenine, 4-Cl-KYN, VistaGen, USA) is a prodrug of 7-chloro-kynurenic acid (7-Cl-KYNA), a potent and highly selective antagonist of NMDAR at the glycine-B co-agonist site [91]. In animal tests of ketamine-like antidepressant actions, 4-chlorokynurenine exhibited rapid, dose-dependent and persistent antidepressant effects following a single treatment [92]. 4-Cl-KYN administration was not associated with the negative side effects of ketamine (rewarding and psychotomimetic effects), and did not induce locomotor sensitization or stereotypic behaviors [92].

4.1.4.2 Recent phase II clinical trials

NCT02484456 is a phase II RCT investigating antidepressant efficacy of AV-101 in subjects with a current or past history of lack of response to one adequate antidepressant trial (Table 5). This study is currently recruiting participants.

4.1.5 AZD6765

4.1.5.1 Background

AZD6765 (AR-R15896AR, Lanicemine, AstraZeneca, UK) is a low-trapping NMDA channel blocker [93] (trapping channel blockade means that the blocking molecule is trapped inside the channel pore [118]). In preliminary RCTs, single or multiple infusions of AZD6765 exhibited antidepressant efficacy without psychotomimetic or dissociative side effects [94].

4.1.5.2 Recent phase II clinical trials

Zarate et al. [95] conducted a phase II RCT (NCT00986479) to evaluate whether a single infusion of AZD6765 could produce rapid antidepressant effects in subjects with TRD (Table 5). The primary outcome measure was the MADRS, which was used to rate overall depressive symptoms at baseline and 60, 80, 110, and 230 minutes post-infusion and on days 1, 2, 3, and 7 post-infusion. AZD6765 infusion was associated with a rapid, but short-lived
improvement of antidepressant efficacy compared with placebo [95]. The drug x time interaction was not significant (p=0.32) [95]. No dissociative side effects were noted.

4.1.5.3 Other development studies

Following the results of study NCT00986479, AstraZeneca discontinued the development of AZD6765 in MDD [119].

4.1.6 Rapastinel

4.1.6.1 Background

Rapastinel (GLYX-13, Allergan) is a NMDAR modulator, acting as functional glycine site weak partial agonist [48, 96]. Preskorn et al. [97] conducted a pilot phase II RCT (NCT01234558) showing that a single intravenous dose of rapastinel reduced depressive symptoms within 2 hours, and this effect was maintained for around 7 days (NCT02192099 is an open-label extension trial).

4.1.6.2 Recent phase II clinical trials

NCT01684163 is a phase II RCT trial investigating the efficacy and safety of rapastinel in subjects with inadequate or partial responses to antidepressants. The study was completed in 2014, but results have not yet been posted to ClinicalTrials.gov.

4.1.6.3 Regulatory aspects

In January 2016 Allergan announced that rapastinel received Breakthrough Therapy Designation from the FDA for adjunctive treatment of MDD [120].

4.1.6.4 Other development studies

Allergan is also developing NRX-1074, a novel antidepressant, with mechanism of action and effects similar to those of rapastinel, but with the advantage of being orally active [121].

4.1.7 RO4995819

4.1.7.1 Background
RO4995819 (RG1578, decoglurant, Roche) is a negative allosteric modulator of mGlu2 and mGlu3 receptors [98].

4.1.7.2 Recent phase II clinical trials

Eudra 2011-002160-24 was a phase II RCT evaluating the antidepressant efficacy of adjunctive RO4995819 in patients with MDD who exhibited inadequate responses to at least one antidepressant treatment (Table 5). The trial was completed in June 2014. Data obtained showed a lack of efficacy [100].

4.1.7.3 Further development studies

Roche terminated the development of RO4995819 in TRD due to a lack of efficacy [99, 100].

4.2 Other psychotropic drugs

4.2.1 Ziprasidone

4.2.1.1 Background

Ziprasidone (Geodon®, Pfizer, USA) is an antipsychotic approved by the FDA for the treatment of schizophrenia and bipolar disorder (acute mania and mixed states) [122]. Its intramuscular injection form was approved for acute agitation in schizophrenia patients. Ziprasidone is now available as a generic medication.

Atypical antipsychotics represent one possible adjunctive therapy for the management of TRD [123]. In particular, ziprasidone has been found to inhibit the neuronal uptake of serotonin and norepinephrine in vitro, with potency comparable to that of the antidepressant imipramine [103]. Papakostas et al. [104] conducted a pilot, open-label trial showing that 10 of 20 patients with TRD (TRD criteria: patients non-responders to an SSRI) had a positive antidepressant response after 6 weeks of ziprasidone augmentation.

4.2.1.2 Recent phase II clinical trials
Papakostas et al. ([102], NCT00633399, Table 5) recently reported a phase II RCT testing the efficacy of adjunctive ziprasidone in 139 adults with unipolar TRD (patients non-responders to 8 weeks of open-label escitalopram). Rates of clinical response (≥ 50% reduction in HDRS score) were significantly greater for the escitalopram+ziprasidone group compared to placebo (Table 5). Adjunctive ziprasidone also exhibited anxiolytic efficacy (secondary outcome measure) [102]. Finally, a greater proportion of patients discontinued adjunctive ziprasidone than placebo (14% vs. 0%) due to intolerance (primarily due to sedation or “activation”-type adverse events: anxiety, agitation, insomnia) [102].

4.2.2 Psilocybin

4.2.2.1 Background

Psilocybin is a mushroom alkaloid, which is rapidly converted by the body to psilocin, a partial agonist for several brain serotonergic receptors, particularly 5-HT\textsubscript{2A}R [105].

4.2.2.2 Recent phase II clinical trials

Carhart-Harris et al. [106] conducted an open-label trial of adjunctive psilocybin in 12 patients with MDD who had failed to respond to at least two courses of antidepressant treatment of different class (Eudra 2013-003196-35; Table 5). There was no control group and patients received psychological support. The acute psychedelic effects peaked 2–3 hours after dosing and declined to negligible levels at least 6 hours after dosing. Depressive symptoms were markedly reduced 1 week and 3 months after high-dose treatment [106].

4.3 Somatic drugs

4.3.1 Minocycline

4.3.1.1 Background

Minocycline is a broad-spectrum tetracycline antibiotic (generic medication) used for the treatment of acne vulgaris and other skin infections [107]. A large number of studies have
reported pleiotropic effects of minocycline in animal models and humans, including anti-inflammatory and neuroprotective actions (for references, see [108]). A small, open-label study suggested that adjunctive minocycline can be effective and well tolerated in TRD [109].

4.3.1.2 Recent phase II clinical trials

NCT02456948 is a RCT evaluating the antidepressant efficacy of adjunctive minocycline in patients resistant to standard antidepressant treatment (AD-ST) with escitalopram, citalopram, venlafaxine, or mirtazapine monotherapy. Treatment-resistance to AD-ST will be assessed with the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (MGH-ATRQ) [124]. Patients will have suffered from TRD for at least 6 weeks in the current episode and will have been at a stable regimen for at least 14 days prior to baseline. The dose and duration of AD-ST must be verifiable (Table 5). This study is currently recruiting participants.

4.3.1.3 Other development studies

A RCT (incorrectly designated as a Phase IV study) is currently recruiting participants to evaluate the antidepressant efficacy of minocycline in patients with TRD (NCT02263872 [108]; see also [110]).

4.3.2 Tocilizumab

4.3.2.1 Background

Tocilizumab (Actemra®, Roche, Switzerland) is a humanized monoclonal antibody against the interleukin-6 receptor (IL-6), used as immunosuppressive agent for the treatment of rheumatoid arthritis [111]. It has previously been reported that IL-6 and/or inflammatory mediators may play a role in the development of depression [125-127], and a recent meta-analysis [128] showed that anti-inflammatory treatment reduced depressive symptoms.

4.3.2.2 Recent phase II clinical trials
NCT02660528 is a phase II single-arm, open-label trial designed to evaluate the antidepressant effects of tocilizumab among patients with treatment-refractory major depression (TRD criteria: MDD after treatment for depression for a minimum of 8 weeks) (Table 5).

4.3.3 Sirukumab

4.3.3.1 Background
Sirukumab (Janssen Biotech, USA) is an anti-IL-6 human monoclonal antibody in development for the treatment of rheumatoid arthritis [112].

4.3.3.2 Phase II clinical trials
Eudra 2014-005206-37 is a RCT evaluating the antidepressant efficacy of subcutaneous sirukumab in patients with MDD non-responders to monoaminergic antidepressants (<25% improvement in HDRS total score) from the screening to baseline visits. This study is ongoing in Poland (other trial sites are planned in Canada, Russia, UK and the USA).

5. Conclusions

A substantial amount of effort is being expended in the area of TRD-targeted therapies, with five compounds in phase III clinical development and twelve other compounds in phase II clinical trials. A single intravenous dose of the glutamatergic modulator ketamine produces a robust and rapid antidepressant effect in persons with TRD; this effect continues to remain significant for 1 week. This observation was a turning point that opened the way for the development and testing of other, more selective NMDAR antagonists for the treatment of TRD. Of these, intranasal esketamine recently entered phase III development and others are in phase II clinical trials (AVP-786, AVP-923, AV-101 and rapastinel). In contrast, disappointing results have been obtained with the NMDA antagonists CERC-301 and
AZD6765 (low-trapping), as well as with the mGlu2/3R antagonist RO4995819. These negative results can be explained by animal studies suggesting that the antidepressant action of ketamine is independent of NMDAR inhibition but rather involve AMPAR activation via a ketamine metabolite.

Of the remaining compounds, the atypical antipsychotic ziprasidone demonstrated efficacy in a phase II trial with an adequate number of participants. Positive results in small pilot studies with the mushroom alkaloid psilocybin and the opioid buprenorphine deserve further investigation with larger sample sizes. Finally, monoclonal antibodies open the possibility of highly innovative therapeutic options, based on new pathophysiological approaches to managing depression.

6. Expert commentary

6.1 Key findings and weakness of previous research with antidepressants

6.1.1 Currently available antidepressants

Monoaminergic drugs are the cornerstone of current MDD treatment [129, 130]. Thus, all available antidepressants increase levels of serotonin, norepinephrine and/or dopamine through different pharmacologic mechanisms [129]. First-generation antidepressants include monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants (TCAs). MAOIs act by inhibiting monoamine oxidase activity, thus preventing the breakdown of monoamine neurotransmitters. However, because of their potentially lethal dietary and drug interaction potential, MAOIs are usually reserved as a last line of treatment [131]. Most TCAs act primarily by blocking serotonin and/or norepinephrine reuptake, thus increasing the synaptic concentrations of these neurotransmitters. However, many TCAs also have high affinity for
several other brain receptors, including adrenergic, histaminergic, cholinergic, NMDA, and opioid receptors [132], some of which are responsible for their more pronounced adverse effects.

Due to frequent undesirable side effects and toxic effects in overdose, TCAs have been replaced by second-generation antidepressants, including SSRIs and serotonin-norepinephrine reuptake inhibitors (SNRIs), however, the newer antidepressants themselves are not devoid of adverse effects either [133]. Moreover, currently available antidepressants often take weeks to months to exert their full therapeutic effects, commonly resulting in considerable morbidity and increased risk for suicidal behavior [134-136].

6.1.2 Current TRD treatment

According to the APA (American Psychiatric Association)-guidelines [130], the prescriber should consider a change in treatment for patients who have not fully responded to an adequate acute-phase treatment for a sufficient time, generally 4–8 weeks. The treatment plan can be revised by implementing one of several therapeutic options, including optimizing the initial treatment, adding a drug that is not traditionally used as an antidepressant (augmentation), changing to a different treatment (switch), or combining two or more antidepressants [1, 7, 130, 137-139].

Generally speaking, optimization consists of increasing antidepressant doses, as tolerated, at least to standard maximal doses for 6 to 12 weeks [7]. The addition of a non-antidepressant medication (augmentation) is a logical next strategy when a patient experiences at least a partial response to the initial agent [7]. First-line adjunctive medications are atypical antipsychotics [1, 7], lithium [19] and thyroid hormone [20]. Switching can be another option following optimization failure, in cases of poor tolerability of an initial antidepressant or in case of complete non-response [7]. The combination of two or more antidepressant
treatments, typically with antidepressants from two different mechanistic classes (especially mirtazapine and bupropion), allows creating a broader spectrum antidepressant regimen. Finally, neurostimulation and neuromodulation strategies are another option for subjects responding insufficiently to pharmacotherapy or psychosocial interventions [1, 23-26].

Well-controlled recurrence prevention trials comparing the above strategies are largely unavailable [1]. Moreover, adding second-line agents to treatment regimens of non-responders can create an additional burden on both patients and healthcare providers. In particular, antipsychotic use is associated with significant side effects such as weight gain, akathisia, and sedation [18].

In spite of the above strategies, many patients with MDD remain non-responders [7]. These patients are at increased risk of severe cognitive impairment, low functioning, comorbid illnesses, suicide and financial burden to the health system [4].

6.2 Recent clinical research with antidepressants

6.2.1 Ketamine for TRD treatment

A new era for antidepressant research has been recently opened up by the demonstration by Zarate et al. [39] of the robust and rapid antidepressant effect of a single intravenous administration of low-dose ketamine in persons with TRD. The exciting prospect of a rapid-acting antidepressant raised much interest, as shown by the numerous contributions to the medical literature and scientific meetings [35-38, 41, 42, 46, 48-52, 54-57]. The antidepressant efficacy of single-dose ketamine was confirmed in a sufficient number of RCTs. The antidepressant action lasted for at least 3 days, in clear excess of what would be predicted by ketamine’s short elimination half-life (2–3 h). Side effects, including increases in blood pressure and heart rate, confusion and dissociation were generally mild and transient.
One special issue was maintaining the antidepressant efficacy of ketamine over the longer term [35, 36, 38, 41, 51, 53, 54, 140]. Repeated dosing with intravenous ketamine given over ≤ 2 weeks was associated with greater reductions in depressive symptoms and longer duration of the anti-depressive action as compared to a single ketamine infusion [36, 38, 46, 140]. Moreover, rapid and sustained reductions in suicidal ideation were observed following repeated doses of intravenous ketamine [51]. However, a number of major unresolved issues remain. First, there is a lack of safety data regarding the long-term ketamine dosing [41, 46, 53]. Indeed, the long-term antidepressant and remission potential of ketamine is challenged by its addictive properties, the dissociative psychotomimetic side-effects and the elevation of blood pressure [41, 46, 52]. Second, it is also unclear whether the usual dose of 0.5 mg/kg is the optimal dose level [41]. Finally, there have been few investigations concerning the antidepressant response to ketamine when given via other administration routes [41]. There is evidence for efficacy of oral ketamine from one small open-label study [54] and one additional, small RCT [55]. Early controlled studies of intranasal or serial infusion ketamine therapy appear promising [46]. A few other studies have investigated the efficacy of ketamine by intramuscular or subcutaneous injection [41].

A large body of evidence indicates that glutamate homeostasis and neurotransmission are disrupted in MDD [35, 56, 141-143]. The mechanism of action of ketamine was therefore expected to involve glutamate receptor function [37, 49, 56, 141-143]. This hypothesis was supported by positron emission tomography/magnetic resonance imaging studies showing that the rapid antidepressant action of ketamine facilitates glutamatergic neurotransmission through blocking the NMDA receptors resulting in increased glutamate in the prefrontal cortex (PFC) [50, 58].
Stress and depression are associated with neuronal atrophy and a loss of synaptic connections, particularly in the PFC and hippocampus (for review, see ref. [143]). Animal studies showed that the rapid antidepressant action of ketamine is associated with synapse formation in the medial PFC, an effect likely due to an increase in brain-derived neurotrophic factor (BDNF) [143, 144].

The perspective of ketamine as a novel treatment for the rapid reduction of symptoms in depressed patients has raised considerable interest among clinicians, patients, and the pharmaceutical industry, leading to the increasing off-label use of ketamine in TRD [41, 46, 53]. However, a controversy was raised based on the lack of well-controlled, long-term trials and the risk of potential harm [41, 53]. Psychiatrists are raising ethical concerns in the UK [53]. Similarly, a Canadian agency did not recommend prescribing ketamine to treat depressive disorders [53], and recent actions have been taken by health authorities in Australia to curtail off-label use of ketamine in TRD [41]. In the American Journal of Psychiatry, its Editor-in-Chief, Robert Freedman, opined that, in addition to concerns over ketamine’s stimulant and opioid properties that make it susceptible to overuse, there is a need to design studies that will adequately assess clinical utility in the long term, including comparisons with currently available augmentation strategies [145]. Moreover, Freedman [145] recommended that more thought be given regarding the definition of TRD that should be used in ketamine trials; given the availability of safer treatments, too liberal a threshold for TRD can be problematic here.

6.2.2 Intranasal esketamine

Aside from ketamine, the most advanced NMDAR antagonist for TRD is esketamine (S-ketamine) [61, 64]. Janssen R&D (USA) is studying intranasal esketamine as a therapy for TRD and also as a medication for patients in whom suicide is an imminent risk. Following
positive phase II RCTs in TRD [61], Janssen launched a phase III development program for adjunctive intranasal esketamine in TRD (Table 3).

A recent study in mice showed that the antidepressant action of ketamine is independent of NMDAR inhibition, but involves early and sustained AMPARs activation via a R-ketamine metabolite [57]. Care should be taken to extrapolate these results to humans, because R-ketamine exhibited greater potency and longer-lasting antidepressant effects in comparison to S-ketamine in mice [62], which is different from adults. Therefore, the antidepressant role of ketamine enantiomers and metabolites in humans clearly deserves further investigation.

6.2.3 Other NMDAR antagonists

Ketamine is limited as a treatment for TRD by its dissociative and psychotomimetic effects and by the need for intravenous administration. There is an urgent need, therefore, to identify well-tolerated, orally available compounds that target the glutamatergic system/NMDA receptors as a novel treatment approach to TRD.

New NMDAR antagonists (modulators) are therefore continuously being introduced for use in TRD [13, 48, 49, 88-90, 94-97]. These show relatively modest antidepressant effects compared to ketamine, but some are orally bioavailable and/or have shown more favourable tolerability profiles (reduced dissociative and/or psychotomimetic effects) [13].

The orally bioavailable, highly selective NMDAR antagonist CERC-301 (acting at the NR2B subunit) is one compound that did not meet its primary endpoint in a phase II RCT [90]. According to Paterson et al. [90], the lack of efficacy may reflect sub-optimal dosing (the low tested dose, daily rather than intermittent dosing) or the patient population selected for the study (depressed patients with recent suicidal ideation). Subsequently, another phase II RCT was launched to evaluate the antidepressant effect of intermittent doses CERC-301 (Table 5). However, another possibility is that the antidepressant action of ketamine itself
may include actions at other receptors, which may explain why ketamine is efficacious, but why other related compounds are not. For instance, ketamine inhibits the reuptake of serotonin, dopamine, and norepinephrine [44]. Similar considerations could explain the negative results obtained with the low-trapping NMADR antagonist AZD6765 [95] and with the mGlu2/3R antagonist RO4995819 [99, 100].

Remaining NMDAR antagonists currently tested in phase II RCTs include the orally available AVP-923 [84, 85] and AVP 786 [87], AV-101 (a potent and highly selective antagonist of the NMDAR at the glycine-B co-agonist site) [91, 92] and rapastinel, a weak partial allosteric agonist at the glycine site of the NMDA receptor complex [96].

6.2.4 Non-NMDA antagonists

Opioid receptor modulators. Researchers had a strong preclinical rationale for investigating buprenorphine and the buprenorphine containing agent ALKS 5461 in the context of TRD [69-71], as well as positive results in proof-of-concept phase II studies [67, 72], which largely justified phase III development. However, negative results were found in two out of three phase III RCTs with ALKS 5461 [80]. Results from a third phase III study with ALKS 5461, as well as from two phase II studies with buprenorphine (NCT02263248 and NCT NCT02181231), may help provide a more definitive answer. Finally, on a cautionary note, a recent study by Ray et al. [146] demonstrated that the prescription of long-acting opioids was associated with a significantly increased risk of all-cause mortality (including deaths from causes other than overdose).

Atypical antipsychotics. A recent phase II RCT reported that adjunctive ziprasidone reduces depression and anxiety in TRD [102]. Ziprasidone was approved by the FDA for the treatment of schizophrenia and bipolar disorder [122], but it is used off-label for depression. Interest in its use for TRD stems from its favorable side effect profile, consisting of less
weight gain and metabolic adverse effects compared to other antipsychotics. However, its association with prolongation of the ECG QTc interval makes it a poor choice to combine with some antidepressants, such as citalopram that also prolong QTc [147, 148].

Brexpiprazole is an atypical antipsychotic with a favorable side effect profile [17]. In contrast to ziprasidone, brexpiprazole has already been approved by the FDA as an adjunctive antidepressant treatment in MDD [73] [73], and serves as an alternative to adjunctive aripiprazole, adjunctive quetiapine extended-release, or olanzapine-fluoxetine combination.

Cariprazine failed to demonstrate efficacy in a phase III RCT in patients with TRD [77]. However, Allergan plan to move forward with another Phase III study of cariprazine in adjunctive MDD [77].

Similarly to ketamine, one important issue is maintaining the antidepressant efficacy of atypical antipsychotics over the longer term. This problem should be evaluated in continuation or maintenance treatment of patients with TRD.

Monoclonal antibodies. Two anti-IL6 monoclonal antibodies (tocilizumab and sirukumab) are in phase II clinical trials for TRD. However, the results of human studies concerning IL-6 are controversial, given the uncertain relationship between IL-6 and depression. In 2013, a meta-analysis of three studies found that raised plasma levels of IL-6 had a small and statistically borderline association with the subsequent development of depressive symptoms [125]. In another study, high IL-6 blood levels in childhood were found to be associated with an increased risk of developing depression in young adulthood [126], but not in a prospective analysis of 4,756 women (who were depression-free up to 1996) over a follow-up of 6-18 years [101]. Finally, IL-6 seems to play a role in the progression and severity of some cancer types [149].
Psilocybin. The positive results of small pilot studies of the mushroom alkaloid psilocybin in TRD [106] deserve further investigation in larger samples.

7. Five-year view

NMDAR antagonists likely represent a very promising alternative treatment for TRD. A large amount of data is being generated through clinical trials of ketamine, esketamine and an increasing number of new non-ketamine NMDAR antagonist compounds and compounds with novel mechanisms not restricted to monoamine transmitter modulation.

Advances in the mechanism of action of investigational antidepressants, as well as the neurobiology of depressive subtypes, are important steps for the development of targeted therapies [7]. Aside from monoamines, glutamate and inflammatory targets, BDNF is a promising target for the development of new antidepressants, as suggested by numerous studies reporting reduced levels of neurotrophic factors in depression [28, 143].

7.1 Methodological aspects

There are no universally accepted criteria for defining TRD and diagnostic tools are sometime lacking [3]. This is mirrored by the clinical trials reviewed here, which used a variety of clinical criteria to identify and include TRD patients, but only some of them verified that the TRD diagnosis was accurate for all enrolled subjects using a reliable and validated questionnaire/assessment. Notably, clinical researchers used many tools for identifying TRD, such as the Antidepressant Treatment History Form [150] and the Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (ATRQ) [124] (see also reference [138]). A standardized approach would be preferable in order to be able to appropriately compare studies.
Specific tools for identifying TRD can be helpful in clinical practice. Indeed, accurately identifying TRD is a prerequisite for optimally changing treatment regimens to help patients achieve remission [139]. Evidence indicates that large numbers of depressed patients are undertreated, resulting in prolonged episodes and the appearance of "pseudo-resistance" [2, 150]. Therefore, the lack of response to previous antidepressant treatment should be assessed using specific instruments to precisely define the level of therapeutic resistance [2, 150].

The development of biomarkers that could identify non-responsive patients or predict antidepressant response may be one strategy to enhance TRD detection or signal detection of treatment efficacy in clinical trials. The CAN-BIND research program investigates and identifies neuroimaging, electrophysiological, molecular and clinical biomarkers to predict outcomes in patients with MDD treated with antidepressant medication [151]. The stratification of patients on the basis of genetic biomarkers may be facilitated by further developments in genetic testing.

The combination of pharmacological treatments with psychosocial/behavioral approaches to TRD has been insufficiently studied and deserves further investigation. Finally, clinical trials of long-term recurrence prevention in TRD are needed.

7.2 Social disability and functional recovery

In the context of clinical trials on TRD, symptom improvement remains the focus for the regulatory approval of new medications. However, patients with TRD frequently present with impaired social functioning because of sustained depressive symptoms [152] and functional outcomes do not always correspond to symptom-based outcomes [153]. Moreover, functional recovery is increasingly recognized as a priority in the treatment of MDD [153]. Therefore, functional outcomes are meaningful evaluation criteria to be included in future TRD trials.
In conclusion, we could see the arrival of the first robust and rapid antidepressant drug in the near future, which would strongly facilitate the ultimate goal of recovery in persons with TRD.

**Key issues**

- Treatment-resistant depression (TRD) represents at least 15%-30% of major depressive disorder (MDD) cases and may cause severe impairment in cognitive functioning, increased risk of developing comorbid illnesses, decreased workplace performance, increased risk of suicide and personal suffering, and increased health care costs.

- We evaluated how the pharmacotherapy of TRD is likely to evolve in the near future. For that purpose, we cataloged and appraised medications currently in phase II/III of clinical development, using the clinical trial registries of the NIH (National Institutes of Health, USA) and the EMA (European Medicines Agency).

- Eighteen investigational compounds were identified. Among them, the NMDA receptor (NMDAR) antagonist ketamine produces a robust and rapid antidepressant effect in persons with TRD. This observation was a turning point that opened the way for other, more selective NMDAR antagonists, which are expected to be better tolerated and/or easier to administer. Of these, intranasal esketamine recently initiated phase III development, and AVP-786, AVP-923, AV-101, and rapastinel (an NMDAR modulator) are in phase II clinical trials.

- Disappointing results have been obtained with the NMDA antagonists CERC-301 and AZD6765 (low-trapping), as well as with the mGlu2/3R antagonist RO4995819. These negative results can be explained by animal studies showing that the antidepressant action
of ketamine may well be independent of NMDAR inhibition, but rather involve AMPAR activation via a ketamine metabolite.

- Of the remaining compounds, the atypical antipsychotic ziprasidone demonstrated efficacy in a phase II trial with an adequate number of participants.
- Glutamatergic agents likely represent a very promising alternative to monoaminergic antidepressants. A large amount of data is being generated with ketamine, esketamine and an increasing number of new compounds. We could see the arrival of the first robust and rapidly-acting antidepressant drug in the near future, which would strongly facilitate the ultimate goal of recovery in persons with TRD.

**Acknowledgements**

The authors are grateful to Greg Panico (Janssen Research & Development, USA) for providing information about intranasal esketamine.

**Funding**

This paper was not funded.

**Declaration of Interest**

R.P. Garay is President of a non-profit association for therapeutic innovation (Craven, Villemoisson-sur-Orge, France). C.A. Zarate is listed as co-inventor on a patent application for the use of (2R,6R)-hydroxynorketamine and (2S,6S)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation and post-traumatic stress disorders. C.A. Zarate has assigned his patent rights to the U.S. government but will share a percent of royalties that may be received by the government. T. Charpeaud declares consultant activities and conferences for AstraZeneca, BMS, Janssen, Otsuka; invitation to Congress by Janssen, Lundbeck, Otsuka; and research activities for AMGEN, Janssen and Lilly. In the past 36 months L. Citrome has engaged in collaborative research with, or received consulting or speaking fees, from: Acadia, Alexza, Alkermes, Allergan, AstraZeneca, Avanir, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Forum, Genentech, Janssen, Jazz, Lundbeck, Merck, Medivation, Mylan, Novartis, Noven, Otsuka, Pfizer, Reckitt Benckiser, Reviva, Shire, Sunovion, Takeda, Teva, Valeant, Vanda. C.U. Correll has been a consultant and/or advisor to or has received honoraria from Alkermes, Forum, Gerson Lehrman Group,
IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, Medavante, Medscape, Neurocrine, Otsuka, Pfizer, ProPhase, Sunovion, Supernus, Takeda, and Teva. He has provided expert testimony for Bristol-Myers Squibb, Janssen and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck and Pfizer. He received grant support from Takeda. A Hameg is a member of a non-profit association for therapeutic innovation (Craven, Villemoisson-sur-Orge, France). P.M. Llorca declares grant support in addition to support for consultancy, expertise and honoraria for conferences from AstraZeneca, Bristol-Myers Squibb, Eli Lilly & Co., Janssen-Cilag, Lundbeck A/S, Otsuka, Roche, and Sanofi Aventis. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
References

Reference annotations

* Of interest
** Of considerable interest


*Treatment strategies in TRD

14. Kim YK, Na KS. Role of glutamate receptors and glial cells in the pathophysiology of treatment-resistant depression. Prog Neuropsychopharmacol Biol Psychiatry 2016;

16. Citrome L. Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Postgrad Med 2010;122:39-48

17. Citrome L. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 2015;69:978-97


*Regulatory guidelines for clinical trials in depression, including TRD


**Demonstration of the rapid and robust antidepressant action of sub-anesthetic doses of intravenous ketamine in TRD

40. Kurdi MS, Theerth KA, Deva RS. Ketamine: Current applications in anesthesia, pain, and critical care. Anesthesia, Essays and Researches 2014;8:283-90

41. Loo CD. Is ketamine ready to be used clinically for the treatment of depression?. Med J Aust 2015;203:425-6


47. Kapur S, Seeman, P. NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia. Mol Psychiatry 2002;7:837-44

*In mice, the antidepressant action of ketamine is independan of NMDAR inhibition


60. Domino EF. Taming the ketamine tiger. 1965. Anesthesiology 2010;113:678-84


**Antidepressant action of intranasal esketamine in TRD


*Antidepressant action of intravenous esketamine in TRD


**The FDA grants breakthrough therapy designation for intranasal esketamine in MDD with imminent risk for suicide**


82. Thase ME, Youakim JM, Skuban A, et al. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-


84. FDA. Food and Drug Administration. Drugs@FDA. Nuedexta. Drug approval package. 2010 [Accessed on June 8, 2016]. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021879Orig1s000TOC.cfm.


96. Moskal JR, Burgdorf JS, Stanton PK, et al. The Development of Rapastinel (Formerly GLYX-13); a rapid acting and long lasting antidepressant. Curr Neuropharmacol 2016;
105. Halberstadt AL, Geyer MA. Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology 2011;61:364-81

111. Venkiteshwaran A. Tocilizumab. MAbs 2009;1:432-8


*The FDA grants breakthrough therapy designation for rapastinel for adjunctive treatment of MDD.


129. Penn E, Tracy DK. The drugs don't work? antidepressants and the current and future pharmacological management of depression. Ther Adv Psychopharmacol 2012;2:179-88


141. Pittenger C, Sanacora G, Krystal JH. The NMDA receptor as a therapeutic target in major depressive disorder. CNS Neurol Disord Drug Targets 2007;6:101-15
144. Li N, Lee B, Liu RJ, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010;329:959-64
**Figure legends**

**Figure 1.** Status of investigational drugs in recent phase II/III clinical trials for TRD. *FDA-approved as an adjunctive therapy to antidepressants for the treatment of major depressive disorder.*

- **FDA-approved** (N=1)
  - Brexpiprazole

- **Investigational compounds in recent clinical trials for treatment-resistant depression (N=18)**
  - Negative results (N=2)
    - AZD6765
    - RO4995819
  - Under investigation (N=8)
    - AVP-923
    - AVP-786
    - CERC-301
    - AV-101
    - Rapastinel
    - Minocycline
    - Tocilizumab
    - Sirukumab
  - Positive results (N=2)
    - Ziprasidone
    - Psilocybin
  - Under investigation (N=5)
    - Ketamine
    - Esketamine
    - Buprenorphine
    - ALKS 5461
    - Cariprazine
Table 1. Investigational drugs for treatment-resistant depression reviewed in this article.

<table>
<thead>
<tr>
<th>Phase</th>
<th>Family</th>
<th>Compound</th>
<th>Main pharmacological action</th>
<th>Main medication uses</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase III</td>
<td>Glutamatergic agents</td>
<td>Ketamine</td>
<td>NMDAR antagonist(^\text{§})</td>
<td>Anesthetic, sedative</td>
<td>[35-60]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Esketamine</td>
<td>NMDAR antagonist(^\text{§})</td>
<td>Investigational New Drug</td>
<td>[43, 60-65]</td>
</tr>
<tr>
<td></td>
<td>Opioids</td>
<td>Buprenorphine</td>
<td>OR modulator(^\text{§})</td>
<td>Opioid addiction</td>
<td>[66-70]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ALKS 5461(^\text{#})</td>
<td>OR modulator(^\text{§})</td>
<td>Investigational New Drug</td>
<td>[71,72]</td>
</tr>
<tr>
<td></td>
<td>Atypical antipsychotics</td>
<td>Brexipiprazole(^\text{##})</td>
<td>D(_2)R partial agonist</td>
<td>Schizophrenia, BD, MDD</td>
<td>[17, 73, 74]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cariprazine</td>
<td>D(_3)/D(_2) partial agonist</td>
<td>Schizophrenia, BD</td>
<td>[75-77]</td>
</tr>
<tr>
<td>Phase II</td>
<td>Glutamatergic agents</td>
<td>AVP-923</td>
<td>NMDAR antagonist(^\text{§})</td>
<td>Pseudo-bulbar affect</td>
<td>[84-86]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AVP-786</td>
<td>NMDAR antagonist(^\text{§})</td>
<td>Investigational New Drug</td>
<td>[87]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CERC-301</td>
<td>NMDAR antagonist(^\text{§})</td>
<td>Investigational New Drug</td>
<td>[48, 88-90]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AV-101</td>
<td>NMDAR antagonist(^\text{§})</td>
<td>Investigational New Drug</td>
<td>[91, 92]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AZD6765</td>
<td>NMDAR antagonist(^\text{§})</td>
<td>Investigational New Drug</td>
<td>[93-95]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rapastinel</td>
<td>NMDAR antagonist(^\text{§})</td>
<td>Investigational New Drug</td>
<td>[96,97]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RO4995819</td>
<td>mGlu(_2/3)R antagonist</td>
<td>Investigational New Drug</td>
<td>[98-100]</td>
</tr>
<tr>
<td>Phase II</td>
<td>Atypical antipsychotics</td>
<td>Ziprasidone</td>
<td>D(<em>2)R and 5-HT(</em>{2A}) antagonist</td>
<td>Schizophrenia, BD</td>
<td>[101-104]</td>
</tr>
<tr>
<td></td>
<td>Psychedelics</td>
<td>Psilocybin</td>
<td>5-HT(_{2A})R partial agonist(^\text{§})</td>
<td>Investigational New Drug</td>
<td>[105, 106]</td>
</tr>
<tr>
<td></td>
<td>Tetracycline antibiotics</td>
<td>Minocycline</td>
<td>Bacteriostatic</td>
<td>Skin infections</td>
<td>[107-110]</td>
</tr>
<tr>
<td></td>
<td>Monoclonal antibodies</td>
<td>Tocilizumab</td>
<td>IL-6R antagonist</td>
<td>Rheumatoid arthritis</td>
<td>[111]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sirukumab</td>
<td>IL-6R antagonist</td>
<td>Investigational New Drug</td>
<td>[112]</td>
</tr>
</tbody>
</table>

\(^\text{#}\)Buprenorphine + samidorphan. FDA-approved compound for MDD treatment, currently in Phase III/IV development (see text). \(^\text{#}\)See text. 5-HT2AR, serotonin 2A receptor. BD, bipolar disorder. D2R, dopamine D2 receptor. MDD, major depressive disorder. mGlu2/3 R, metabotropic glutamate 2/3 receptor. NMDAR, N-methyl-D-aspartate receptor antagonists. OR, opioid receptor. IL-6R, interleukin-6 receptor.
Table 2. Recent clinical trials with ketamine in treatment-resistant depression (2014 and later).

<table>
<thead>
<tr>
<th>Phase</th>
<th>Sponsor</th>
<th>Identifier</th>
<th>Primary outcome</th>
<th>Time frame</th>
<th>N#</th>
<th>Results or status</th>
</tr>
</thead>
<tbody>
<tr>
<td>III</td>
<td>VA Office of R&amp;D (USA)</td>
<td>NCT02556606</td>
<td>Time to relapse</td>
<td>4 W</td>
<td>72</td>
<td>March 2020£</td>
</tr>
<tr>
<td>II/III</td>
<td>University of Ottawa (Canada)</td>
<td>NCT01945047</td>
<td>Safety &amp; HDRS§</td>
<td>2 W</td>
<td>63</td>
<td>December 2015&amp;</td>
</tr>
<tr>
<td></td>
<td>Janssen R&amp;D (USA)</td>
<td>Singh et al, 2016 [38]</td>
<td>MADRS§§</td>
<td>15 D</td>
<td>68</td>
<td>KET= -17.7*£, PL= -3.1</td>
</tr>
<tr>
<td></td>
<td>Massachusetts General Hospital (USA)</td>
<td>NCT01920555</td>
<td>HDRS§</td>
<td>24 H</td>
<td>100</td>
<td>January 2016&amp;</td>
</tr>
<tr>
<td></td>
<td>Veteran’s Affairs Office R&amp;D (USA)</td>
<td>NCT02360280</td>
<td>MADRS§§</td>
<td>13 D</td>
<td>56</td>
<td>January 2018&amp;</td>
</tr>
<tr>
<td>II</td>
<td>Paul J. Lamothe§ (Mexico)</td>
<td>NCT01868802</td>
<td>HDRS§</td>
<td>1-7 D</td>
<td>60</td>
<td>May 2016&amp;</td>
</tr>
<tr>
<td></td>
<td>Magdeburg University $$$ (Germany)</td>
<td>EU 2010-023414-31</td>
<td>HDRS§</td>
<td>24 H</td>
<td>40</td>
<td>NC</td>
</tr>
<tr>
<td></td>
<td>University of Minnesota $$$ (USA)</td>
<td>NCT02078817</td>
<td>CGI</td>
<td>1 W</td>
<td>20</td>
<td>April 2016&amp;</td>
</tr>
<tr>
<td></td>
<td>Mayo Clinic (USA)</td>
<td>NCT02094898</td>
<td>MADRS§§</td>
<td>8 W£</td>
<td>30</td>
<td>June 2016&amp;</td>
</tr>
</tbody>
</table>

*Enrolment (final or estimated). £Primary completion date (past or estimated). §Intravenous ketamine at 0.5 mg/kg, thrice-weekly. *Statistically significant. §American British Cowdray Medical Center. $$$Clinical and Translational Science Institute. $$$Department of Psychiatry, School of Medicine. £Maintenance treatment (4 weeks) + follow up after treatment ends for four weeks. §Hamilton Depression Rating Scale. §§Montgomery–Asberg Depression Rating Scale.

Table 3. Recent clinical trials with esketamine in treatment-resistant depression (2014 and later).

<table>
<thead>
<tr>
<th>Phase</th>
<th>Sponsor</th>
<th>Identifier</th>
<th>Primary outcome</th>
<th>Time frame</th>
<th>N</th>
<th>Results or status</th>
</tr>
</thead>
<tbody>
<tr>
<td>III</td>
<td>Janssen R&amp;D (USA)</td>
<td>TRANSFORM-1</td>
<td>MADRS§</td>
<td>4 W</td>
<td>348</td>
<td>October 2017§</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TRANSFORM-2</td>
<td>MADRS§</td>
<td>4 W</td>
<td>196</td>
<td>March 2017§</td>
</tr>
<tr>
<td></td>
<td>Janssen R&amp;D (USA)</td>
<td>TRANSFORM-3</td>
<td>MADRS§</td>
<td>4 W</td>
<td>230</td>
<td>July 2017§</td>
</tr>
<tr>
<td></td>
<td>Janssen R&amp;D (USA)</td>
<td>SUSTAIN-1</td>
<td>Time to relapse§§</td>
<td>104 W</td>
<td>333</td>
<td>August 2017§</td>
</tr>
<tr>
<td></td>
<td>Janssen R&amp;D (USA)</td>
<td>SUSTAIN-2</td>
<td>Safety</td>
<td>56 W</td>
<td>1071</td>
<td>January 2018§</td>
</tr>
<tr>
<td>II</td>
<td>Janssen R&amp;D (USA)</td>
<td>PeRSEVERe</td>
<td>MADRS§§§</td>
<td>12 W</td>
<td>68</td>
<td>ΔScore£: -5.3 ± 2.1*</td>
</tr>
<tr>
<td></td>
<td>Janssen R&amp;D (USA)</td>
<td>SYNAPSE</td>
<td>MADRS§</td>
<td>2 W</td>
<td>108</td>
<td>July 2015§</td>
</tr>
<tr>
<td></td>
<td>Janssen R&amp;D (USA)</td>
<td>Singh et al, 2015 [64]</td>
<td>MADRS§</td>
<td>1 D</td>
<td>30</td>
<td>ESK££= -16.9*, PL= -3.8</td>
</tr>
</tbody>
</table>

*Enrolment (final or estimated). *Primary completion date (past or estimated). *Statistically significant. *Change from baseline in Montgomery–Asberg Depression Rating Scale (MADRS). §§Time to relapse in patients with stable remission. §§§Change from baseline in MADRS total score at day 1 (4 hours post-dose). £Least-square mean difference ± SE, two-sided p=0.015. ££Intravenous esketamine at 0.4 mg/kg. D, days. W, weeks.
Table 4. Recent clinical trials with buprenorphine, ALKS 5461, brexiprazole and cariprazine in treatment-resistant depression (2014 and later).

<table>
<thead>
<tr>
<th>Phase</th>
<th>Sponsor</th>
<th>Identifier</th>
<th>Primary outcome</th>
<th>Time frame</th>
<th>N</th>
<th>Results or status</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Buprenorphine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>University of Pittsburgh (USA)</td>
<td>NCT01407575</td>
<td>MADRS§</td>
<td>6 W</td>
<td>10</td>
<td>Negative? (see text)</td>
</tr>
<tr>
<td>II</td>
<td>University of Pittsburgh (USA)</td>
<td></td>
<td>MADRS§</td>
<td>8 W</td>
<td>15</td>
<td>-17.5 (No placebo)</td>
</tr>
<tr>
<td>I/II</td>
<td>CAMH (CAN)§</td>
<td>NCT02263248</td>
<td>MADRS§</td>
<td>32 W</td>
<td>72</td>
<td>December 2017§</td>
</tr>
<tr>
<td></td>
<td>Washington University (USA)$$</td>
<td>NCT02181231</td>
<td>MADRS§</td>
<td>32 W</td>
<td>100</td>
<td>August 2018§</td>
</tr>
<tr>
<td>ALKS 5461</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>Alkermes (USA and Ireland)</td>
<td>FORWARD-3</td>
<td>MADRS§</td>
<td>10 W</td>
<td>447</td>
<td>NS</td>
</tr>
<tr>
<td></td>
<td>Alkermes (USA and Ireland)</td>
<td>FORWARD-4</td>
<td>MADRS§</td>
<td>11 W</td>
<td>385</td>
<td>NS</td>
</tr>
<tr>
<td></td>
<td>Alkermes (USA and Ireland)</td>
<td>FORWARD-5</td>
<td>MADRS§</td>
<td>11 W</td>
<td>350</td>
<td>October 2016§</td>
</tr>
<tr>
<td></td>
<td>Alkermes (USA and Ireland)</td>
<td>FORWARD-1</td>
<td>Safety</td>
<td>8 W</td>
<td>66</td>
<td>September 2014§</td>
</tr>
<tr>
<td></td>
<td>Alkermes (USA and Ireland)</td>
<td>FORWARD-2</td>
<td>Safety</td>
<td>56 W</td>
<td>1500</td>
<td>December 2017§</td>
</tr>
<tr>
<td>Brexiprazole</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>Lundbeck (DK)</td>
<td>NCT01838681</td>
<td>Remission</td>
<td>36 W</td>
<td>2193</td>
<td>June 2016§</td>
</tr>
<tr>
<td>Cariprazine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>Forest (USA)</td>
<td>NCT01715805</td>
<td>MADRS§</td>
<td>8 W</td>
<td>1100</td>
<td>Negative</td>
</tr>
<tr>
<td>II</td>
<td>Forest (USA)</td>
<td>Durgam 2016 [76]</td>
<td>MADRS§</td>
<td>8 W</td>
<td>819</td>
<td>-2.2*</td>
</tr>
</tbody>
</table>

§Enrolment (final or estimated). §Primary completion date (past or estimated). §Centre for Addiction and Mental Health (Toronto, Ontario, Canada). $Washington University School of Medicine (USA). §Change from baseline in Montgomery–Asberg Depression Rating Scale (MADRS). NS, non-statistically significant. W, weeks.
Table 5. Investigational drugs in phase II trials for treatment-resistant depression (2014 and later).

<table>
<thead>
<tr>
<th>Compound</th>
<th>Sponsor</th>
<th>Identifier</th>
<th>Primary outcome</th>
<th>Time frame</th>
<th>N</th>
<th>Results or status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glutamatergic agents</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AVP-923</td>
<td>James Murrough (NY, USA)</td>
<td>NCT01882829</td>
<td>MADRS§§</td>
<td>10 W</td>
<td>20</td>
<td>March 2016*</td>
</tr>
<tr>
<td>AVP-786</td>
<td>Avanir (USA)</td>
<td>NCT02153502</td>
<td>MADRS§§</td>
<td>10 W</td>
<td>200</td>
<td>March 2016*</td>
</tr>
<tr>
<td>CERC-301</td>
<td>Cerecor (USA)</td>
<td>Reference [90]</td>
<td>HDRS-17§</td>
<td>5 W</td>
<td>137</td>
<td>NS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NCT02459236</td>
<td>Bech-6§§§</td>
<td>4 D</td>
<td>104</td>
<td>September 2016*</td>
</tr>
<tr>
<td>AV-101</td>
<td>National Institute of Mental Health (USA)</td>
<td>NCT02484456</td>
<td>HDRS§</td>
<td>Multiple</td>
<td>25</td>
<td>December 2019*</td>
</tr>
<tr>
<td>AZD6765</td>
<td>Astra-Zeneca (UK)</td>
<td>Reference [95]</td>
<td>MADRS§§</td>
<td>Multiple</td>
<td>22</td>
<td>Small, transient effect§§</td>
</tr>
<tr>
<td>Rapastinel</td>
<td>Allergan (USA)</td>
<td>NCT01684163</td>
<td>HDRS§</td>
<td>16 W</td>
<td>369</td>
<td>April 2014*</td>
</tr>
<tr>
<td>RO4995819</td>
<td>Hoffmann-La Roche (Switzerland)</td>
<td>2011-002160-24£</td>
<td>MADRS§§</td>
<td>6 W</td>
<td>340</td>
<td>Terminated</td>
</tr>
<tr>
<td>Other psychotropic drugs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ziprasidone</td>
<td>Massachusetts General Hospital (USA)</td>
<td>Reference [102]</td>
<td>HDRS§</td>
<td>8 W</td>
<td>139</td>
<td>ZIP=35% PL=20%*</td>
</tr>
<tr>
<td>Psilocybin</td>
<td>Imperial College London (UK)</td>
<td>Reference [106]</td>
<td>Psychedelic PDE§£</td>
<td>12</td>
<td>Ongoing</td>
<td></td>
</tr>
<tr>
<td>Somatic drugs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Minocycline</td>
<td>Charite University (Germany)</td>
<td>NCT02456948</td>
<td>MADRS§§</td>
<td>6 W</td>
<td>160</td>
<td>February 2019*</td>
</tr>
<tr>
<td>Tocilizumab</td>
<td>Brigham and Women's Hospital (USA)</td>
<td>NCT02660528</td>
<td>MADRS§§</td>
<td>6 W</td>
<td>15</td>
<td>June 2017*</td>
</tr>
<tr>
<td>Sirukumab</td>
<td>Janssen-Cilag International (Poland)</td>
<td>2014-005206-3£</td>
<td>HDRS§</td>
<td>12 W</td>
<td>192</td>
<td>Ongoing</td>
</tr>
</tbody>
</table>

*Enrolment (final or estimated). *Primary completion date (past or estimated). *Statistically significant. 1Hamilton Depression Rating Scale. 2Montgomery–Asberg Depression Rating Scale. 36-item unidimensional subset of the HDRS-17. *Eudra identifier. £Peak drug effects. *Percent of responders (see text). ££See text. D, days. NS, non-statistically significant. PL, placebo. W, weeks. ZIP, ziprasidone.